IRAK4 and neoplasm: After encapsulating erlotinib (an EGFR inhibitor) and siRNA targeting IRAK4 (siIRAK4), the prepared nanodrugs (siIRAK4/Er@GEM‐SS‐PC) were camouflaged by SW1990 pancreatic cancer cell‐RAW264.7 macrophage hybrid membranes, originating biomimetic NPs (siIRAK4/Er@GEM‐SS‐PC‐M), aiming to reduce immune clearance, prolong systemic circulation and enhance homologous tumor‐targeting (Figure 20a,b).